Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
about
Factor Xa inhibitors for acute coronary syndromesXa inhibitors for acute coronary syndromesVenous thromboembolic diseaseEvidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesClinical Scenarios for Discordant Anti-XaVenous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxisA systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiencyGuidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolismAnticoagulation and antiplatelets as prophylaxis for hepatic artery thrombosis after liver transplantationSelecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention.Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide.Update on heparin: what do we need to know?Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesTreating venous thromboembolism in patients with cancer.Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates.Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial.Effect of enoxaparin on peak and trough levels of antifactor Xa in patients with a creatinine clearance of less than 30 mL/minA multi-center, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis--the membrane studyBleeding risk during treatment of acute thrombotic events with subcutaneous LMWH compared to intravenous unfractionated heparin; a systematic review.Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment.Preemptive dosage reduction of nadroparin in patients with renal failure: a retrospective case seriesCardiovascular manifestations of hypereosinophilic syndromes.Clinical Use of Anti-Xa Monitoring in Malignancy-Associated Thrombosis.Impact of anemia on long-term ischemic events and bleeding events in patients undergoing percutaneous coronary intervention: a system review and meta-analysisGuidance for the treatment and prevention of obstetric-associated venous thromboembolism.Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal InsufficiencyPharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and childrenAllosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ibα-binding and heparin-binding site of thrombin.Challenges in managing anticoagulant therapy in patients with heart valve prostheses.Use of enoxaparin in patients with chronic kidney disease: safety considerations.The design and synthesis of new synthetic low-molecular-weight heparins.Prevention and treatment of venous thromboembolism in the elderly patientCurrent update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy.Current strategies in prophylaxis and treatment of venous thromboembolism.Low-molecular-weight heparin in patients with chronic renal insufficiency.Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study.Are all low molecular weight heparins equivalent in the management of venous thromboembolism?Prognostic factors and clinical outcomes of acute intracerebral hemorrhage in patients with chronic kidney disease.Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
P2860
Q24234760-B0D9685A-469E-4399-8F43-23F9391E2B27Q24243766-043C8F82-AACA-47CD-A8C0-08D6E854F07BQ24631121-BF572E77-A3FE-4293-84E4-F7DFA7BD9C04Q24632951-FF2876D8-F503-4517-AFA4-92793411A107Q26746987-7885641C-FF17-4EC5-A2B8-1D7C0313BBECQ26797444-0A287075-BBF8-44AF-B019-2B032917ABA7Q26995027-000879C5-38B6-441E-B42D-F83E972C30E8Q28079081-3002434B-4CF6-454B-B619-861A732D359EQ28088534-E9FB17FF-FC5E-403A-AF04-EC060A1B1122Q30438893-CA398B27-DF31-4A77-A8DB-9EF3251449FEQ33385947-2B0F557D-3D13-4D48-A950-FF834A3A4263Q33386920-DBF8E8FC-3389-488A-8EC7-029158349E78Q33399576-5C625599-1ABB-42E0-9261-0BA733038DD9Q33400564-869FF2E8-6E47-422C-BD35-0FDA9DCDEAB0Q33612746-CCB359A8-1B84-4F7D-A390-B52EE4237A46Q33919099-9D888F16-D02B-452C-A579-D8061C2B6A9CQ33989403-CDBBECF5-32D1-4D45-BD05-E4468477DE10Q34320163-710378C7-EEA9-4558-B1C2-56D11C5F11B6Q34415964-93EC25B9-F796-4BF5-BEB3-B30B45B7C1D0Q35154142-485B8899-6044-4373-B27A-B60857929921Q35154171-F3A127F8-9872-4AD7-9431-BBB754E42E94Q35626540-D7FC5CA8-A8BB-4B50-A510-455A395B6817Q36102877-5C22694D-C8F2-4580-AE3A-BC1D25207AE4Q36205646-7D817EEF-49B6-466D-AD3F-2CF9E363B5FDQ36345688-DF82A1FD-2F56-471B-9465-05F6DCD46A8AQ36471056-7F028652-6816-4578-91E6-99B09D268B87Q36484329-07BC533E-FBFC-4E68-B664-A0E3279580EDQ36510063-B4C18F38-6C99-4947-9302-4878800D146DQ36788507-DD0FFA26-8DE1-4E59-B003-A66CF0C26ED4Q36815991-466240BE-9B34-4D66-8BC8-83EB2277BC89Q36987130-5763A643-CC91-4E25-8550-201412FC559AQ37004231-809220AF-BEDF-4328-99D1-EB2E9D99A867Q37017407-BF09D361-2E81-47E7-BA1A-73F1EA79A501Q37076393-9B8809FB-3997-4326-990D-CD11740BF219Q37165370-501E235B-99E5-4E7A-9D4F-3985992D5450Q37194647-FA07A785-0DFC-452F-8D3D-DE3E935275CFQ37208427-EA3073D5-EA10-47A3-A8B4-8FEEA4A74503Q37278718-986D906D-84ED-4A2E-B258-02F0CBD23E84Q37344655-E5495595-5DA8-4D23-82B1-F651D3B2C2AAQ37490581-865F66BA-7AE3-4907-827D-8EA1121BCA04
P2860
Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Meta-analysis: low-molecular-w ...... th severe renal insufficiency.
@ast
Meta-analysis: low-molecular-w ...... th severe renal insufficiency.
@en
type
label
Meta-analysis: low-molecular-w ...... th severe renal insufficiency.
@ast
Meta-analysis: low-molecular-w ...... th severe renal insufficiency.
@en
prefLabel
Meta-analysis: low-molecular-w ...... th severe renal insufficiency.
@ast
Meta-analysis: low-molecular-w ...... th severe renal insufficiency.
@en
P2093
P1476
Meta-analysis: low-molecular-w ...... th severe renal insufficiency.
@en
P2093
Francesco Dentali
Mark A Crowther
P304
P356
10.7326/0003-4819-144-9-200605020-00011
P407
P577
2006-05-01T00:00:00Z